JP2005535588A - 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト - Google Patents

第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト Download PDF

Info

Publication number
JP2005535588A
JP2005535588A JP2004501452A JP2004501452A JP2005535588A JP 2005535588 A JP2005535588 A JP 2005535588A JP 2004501452 A JP2004501452 A JP 2004501452A JP 2004501452 A JP2004501452 A JP 2004501452A JP 2005535588 A JP2005535588 A JP 2005535588A
Authority
JP
Japan
Prior art keywords
factor viii
amino acid
seq
acid sequence
lrp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004501452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535588A5 (enExample
Inventor
クーンラード メルテンス，
アレンド ニールス ボンフェンスケン，
ヤン フォルベルヒ，
マンフレッド リーゲル，
フリードリッヒ シャイフリンガー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Publication of JP2005535588A publication Critical patent/JP2005535588A/ja
Publication of JP2005535588A5 publication Critical patent/JP2005535588A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2004501452A 2002-04-29 2003-04-28 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト Pending JP2005535588A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37635102P 2002-04-29 2002-04-29
PCT/EP2003/004425 WO2003093313A2 (en) 2002-04-29 2003-04-28 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010130425A Division JP2010202664A (ja) 2002-04-29 2010-06-07 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト

Publications (2)

Publication Number Publication Date
JP2005535588A true JP2005535588A (ja) 2005-11-24
JP2005535588A5 JP2005535588A5 (enExample) 2006-07-06

Family

ID=29401334

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004501452A Pending JP2005535588A (ja) 2002-04-29 2003-04-28 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
JP2010130425A Pending JP2010202664A (ja) 2002-04-29 2010-06-07 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010130425A Pending JP2010202664A (ja) 2002-04-29 2010-06-07 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト

Country Status (10)

Country Link
US (1) US8586538B2 (enExample)
EP (1) EP1497330B1 (enExample)
JP (2) JP2005535588A (enExample)
AT (1) ATE463514T1 (enExample)
AU (1) AU2003227687B2 (enExample)
CA (1) CA2484155C (enExample)
DE (1) DE60332011D1 (enExample)
DK (1) DK1497330T3 (enExample)
ES (1) ES2343681T3 (enExample)
WO (1) WO2003093313A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523663A (ja) * 2008-06-04 2011-08-18 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006003183A1 (de) * 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009274958A (ja) 2006-08-31 2009-11-26 Nara Prefecture 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
JP5394864B2 (ja) * 2009-09-10 2014-01-22 アスモ株式会社 モータ
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
CN103209992A (zh) 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
WO2016000039A1 (en) 2014-07-02 2016-01-07 Csl Limited Modified von willebrand factor
DK3265483T3 (da) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modificeret von Willebrand-faktor med forbedret halveringstid
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
KR20180094114A (ko) 2016-01-07 2018-08-22 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 절단된 폰 빌레브란트 인자
WO2017117630A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated von willebrand factor
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507664A (ja) * 1995-06-12 1999-07-06 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用
WO1999058680A2 (en) * 1998-05-08 1999-11-18 Stichting Sanquin Bloedvoorziening Method for diagnosis and treatment of haemophilia a patients with an inhibitor
WO2000027425A2 (de) * 1998-11-10 2000-05-18 Baxter Aktiengesellschaft Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59914490D1 (de) * 1998-11-10 2007-10-18 Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11507664A (ja) * 1995-06-12 1999-07-06 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用
WO1999058680A2 (en) * 1998-05-08 1999-11-18 Stichting Sanquin Bloedvoorziening Method for diagnosis and treatment of haemophilia a patients with an inhibitor
WO2000027425A2 (de) * 1998-11-10 2000-05-18 Baxter Aktiengesellschaft Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6009028342, Ｂｌｏｏｄ, 2001, Ｖｏｌ．９７, ｐｐ．９６６−９７２ *
JPN6009028345, Ｂｌｏｏｄ, 2000, Ｖｏｌ．９５, ｐｐ．１７０３−８ *
JPN6009028348, Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．, 1999, Ｖｏｌ．２７４, ｐｐ．３７６８５−９２ *
JPN6009028351, Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．, 1999, Ｖｏｌ．２７４, ｐｐ．２３７３４−９ *
JPN6009028354, Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．, 1996, Ｖｏｌ．２７１, ｐｐ．１９３５−４０ *
JPN6009028357, Ｔｒｅｎｄｓ Ｃａｒｄｉｏｖａｓｃ． Ｍｅｄ．, 2001, Ｖｏｌ．１１, ｐｐ．２５１−７ *
JPN6009028359, Ｔｒｅｎｄｓ Ｃａｒｄｉｏｖａｓｃ． Ｍｅｄ．, 2000, Ｖｏｌ．１０, ｐｐ．８−１４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523663A (ja) * 2008-06-04 2011-08-18 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質

Also Published As

Publication number Publication date
CA2484155A1 (en) 2003-11-13
CA2484155C (en) 2015-10-13
ES2343681T3 (es) 2010-08-06
ATE463514T1 (de) 2010-04-15
US8586538B2 (en) 2013-11-19
DE60332011D1 (de) 2010-05-20
DK1497330T3 (da) 2010-06-14
WO2003093313A3 (en) 2004-07-29
EP1497330A2 (en) 2005-01-19
WO2003093313A2 (en) 2003-11-13
JP2010202664A (ja) 2010-09-16
US20080219983A1 (en) 2008-09-11
AU2003227687A1 (en) 2003-11-17
EP1497330B1 (en) 2010-04-07
AU2003227687B2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
JP2010202664A (ja) 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
JP6527918B2 (ja) 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
JP6336522B2 (ja) 細胞取込みが低下した第ｖｉｉｉ因子変異体
TWI573806B (zh) 生物活性胜肽
JP2018104459A (ja) 血友病の治療に適する化合物
US20220213200A1 (en) Anti-gpiib/iiia antibodies or uses thereof
RS66972B1 (sr) Metode lečenja hemofilije a
JP2016522219A (ja) 血友病の治療に適する化合物
JP2015519313A (ja) 血友病の治療に適する医薬組成物
JP2019511457A (ja) 抗ｖｗｆ ｄ’ｄ３単一ドメイン抗体及びそれを含むポリペプチド
EP3065769A1 (en) Procoagulant fusion compound
JP2019516347A (ja) 抗アンチトロンビン単一ドメイン抗体及びそれを含むポリペプチド
AU2021278756A1 (en) ADAMTS13 protein variants and uses thereof
US12171802B2 (en) Compositions for inhibiting fibrin-VLDL receptor-dependent inflammation and methods of treatment
WO2001058475A1 (en) Regulation of platelet adhesion and aggregation
US20030040515A1 (en) Regulation of platelet adhesion and aggregation

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100305

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100721